Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. SI-BONE, Inc.
  6. Summary
    SIBN   US8257041090

SI-BONE, INC.

(SIBN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/19/2022 01/20/2022 01/21/2022 01/24/2022 01/25/2022 Date
21.06(c) 21(c) 20.1(c) 20.7(c) 20.1(c) Last
185 465 158 091 264 274 374 103 154 670 Volume
-2.41% -0.28% -4.29% +2.99% -2.90% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 89,6 M - -
Net income 2021 -55,0 M - -
Net cash position 2021 117 M - -
P/E ratio 2021 -12,1x
Yield 2021 -
Sales 2022 110 M - -
Net income 2022 -45,4 M - -
Net cash position 2022 80,5 M - -
P/E ratio 2022 -14,8x
Yield 2022 -
Capitalization 673 M 673 M -
EV / Sales 2021 6,21x
EV / Sales 2022 5,38x
Nbr of Employees 295
Free-Float -
More Financials
Company
SI-BONE, Inc. is a medical device company. The Company is focused on the development of implantable devices used in the surgical treatment of the sacropelvic anatomy. Its invasive surgical implant system, iFuse, is used to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that often causes severe lower back pain. Its iFuse Implant System includes a series of triangular titanium implants and the... 
More about the company
Ratings of SI-BONE, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about SI-BONE, INC.
01/10SI-Bone Expects Q4 Revenue of $24.9 Million to $25.2 Million
MT
01/10SI BONE : Announces Revenue for the Fourth Quarter and Full Year 2021 - Form 8-K
PU
01/10SI-BONE, INC. : Results of Operations and Financial Condition, Change in Directors or Prin..
AQ
01/10SI BONE : January 2022 Investor Presentation
PU
01/10SI-BONE Announces Revenue for the Fourth Quarter and Full Year 2021
GL
01/10SI-BONE, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2021
CI
2021SI-BONE to participate in 24th Annual Needham Virtual Growth Conference
AQ
2021Truist Securities Adjusts SI-Bone PT to $30 From $35, Maintains Buy Rating
MT
2021SI-BONE, Inc. Announces Updated Exclusive Blue Cross Blue Shield Association Evidence S..
AQ
2021Needham Names SI-Bone 2022 Top Pick, Citing Outpatient Exposure, iFuse-TORQ Potential; ..
MT
2021SI-BONE, INC. Management's Discussion and Analysis of Financial Condition and Results ..
AQ
2021JMP Securities Adjusts Price Target on SI-Bone to $36 from $42, Keeps Market Outperform..
MT
2021Needham Lowers SI-Bone's Price Target to $32 From $37 After Q3 Revenue Miss; Buy Rating..
MT
2021SI-BONE : Q3 Earnings Snapshot
AQ
2021SI-BONE, Inc. Reports Third Quarter 2021 Financial Results and Updates 2021 Financial G..
PU
More news
News in other languages on SI-BONE, INC.
01/10SI-Bone prévoit un chiffre d'affaires de 24,9 à 25,2 millions de dollars pour le quatri..
01/10SI-BONE, Inc. fournit des prévisions de revenus pour le quatrième trimestre et l'année ..
2021Earnings Flash (SIBN) SI-BONE annonce un chiffre d'affaires de 22,3 millions de dollars..
2021SI-BONE, Inc. fournit des prévisions de revenus pour l'ensemble de l'année 2021
2021Earnings Flash (SIBN) SI-BONE affiche un chiffre d'affaires de 20,2 millions de dollars..
More news
Analyst Recommendations on SI-BONE, INC.
More recommendations
Chart SI-BONE, INC.
Duration : Period :
SI-BONE, Inc. Technical Analysis Chart | SIBN | US8257041090 | MarketScreener
Technical analysis trends SI-BONE, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 20,10 $
Average target price 34,29 $
Spread / Average Target 70,6%
EPS Revisions
Managers and Directors
Laura A. Francis Chief Executive Officer & Director
Anshul Maheshwari Chief Financial & Accounting Officer
Jeffrey W. Dunn Executive Chairman
Scott A. Yerby Chief Technology Officer
W. Carlton Reckling Vice President-Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
SI-BONE, INC.-9.50%673
MASIMO CORPORATION-23.66%11 761
GETINGE AB-16.68%9 654
PENUMBRA, INC.-25.84%7 960
NOVOCURE LIMITED-14.21%6 687
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD.-18.28%4 835